Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading
cause of carcinogenic death. To date, surgical resection is regarded as the gold standard by …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

Introduction Colorectal cancer is the fourth most common cancer in the UK. There remains a
need for improved risk stratification following curative resection. Circulating-tumour DNA …

Immunotherapies, especially the programmed cell death 1/programmed cell death ligand 1
(PD-1/PD-L1) inhibitors, have revolutionized the therapeutic strategies of various cancers …

Purpose Nearly 50% of patients recur within two years after curatively intended resection of
colorectal cancer liver metastasis (CRLM). The optimal surveillance strategy is unknown due …

Simple Summary In cancer, disseminated neoplastic cells circulating in blood are a source
of tumor DNA, RNA, and protein, which can be harnessed to diagnose, monitor, and better …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …